BARCELONA, Spain, May 2, 2024 /PRNewswire/ — MGI Tech (MGI), a company committed to creating foundational tools and technologies to lead the Life sciences, today introduced the latest addition to its sequencer portfolio, the DNBSEQ-E25 platform. portable and easy to use, for the European and African market. Additionally, the company presented its current offering of laboratory automation and sequencing products, including the DNBSEQ-G99 and the entire workflow for the Million Microbiomes from Humans (MMHP) project, at the 34eEuropean Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global also known as ECCMID2024). During the event which will be held from April 27 to 30 in Barcelona, MGI and ABL Diagnostics (Woippy, France, Euronext: ABLD? ISIN: FR001400AHX6) are pleased to announce their partnership and the compatibility of ABLDiagnostics’ DeepChek tests with MGI’s DNBSEQtm platforms.
Once again, MGI shows its commitment to supporting healthcare and research as well as applications in Europe and in Africa. At MGI, we believe that the power and potential of genomics are limitless, said Dr. YongHou, Managing Director of MGI Europe and Africa. By making our technology, expertise and technical facilities available, we hope to make it easier for more companies and institutions to develop content on our DNBSEQ platforms, which will empower them to improve health and well-being of all.
Introducing the DNBSEQ-E25portable for European and African customers
The question What if your sequencing capabilities could be mobile?, the answer is that MGI’s flagship product in its series, the DNBSEQ-E25, is a portable, user-friendly sequencer with a daily data rate of up to 7.5G .Built on the new self-luminous biochemical system, the E25 has upgraded its sequencing system, flow cells and sequencing cartridge, while integrating bioinformatics functions. Its ease of installation means it’s ready to go in minutes, and a fast turnaround time means it only takes 20 hours for the PE150 to switch from DNB data to FASTQ data. The DNBSEQ-E25 meets the needs of applications for infectious diseases, small genome sequencing, small panels and strand verification. The sequencer is now available for European and African customers.
Strengthening microbiology laboratories through collaboration with ABL Diagnostics
Additionally, at this year’s ESCMID Global2024, MGI announced a technical evaluation of the solutions by ABLDiagnostics (ABL), a Euronext-listed company that develops molecular biology tests and software for microbiological gnotyping. ABL’s DeepChek assays have been successfully tested on MGI’s DNBSEQ-G400 and DNBSEQ-G99 platforms. Further verification and validation studies of DeepChek tests will also be performed on the new DNBSEQ-E25.
This new technical evaluation with MGI will strengthen our presence in microbiological gnotyping through the verification of our DeepChek assays and software on other next-generation sequencing (NGS) platforms, said DimitriGonzalez, Head of Diagnostics at ABL Diagnostics. It expands access and delivery of new types of NGS technology and end-to-end solutions for microbiology laboratories to cover an ever-increasing portfolio of infectious disease applications, including but not limited to limited to HIV, viral hepatitis, respiratory viruses, tropical infections, and tuberculosis.
ABL offers a unique portfolio of tests and downstream analysis software systems for laboratories seeking to implement microbiological gnotyping through DNA sequencing, covering a wide range of infectious diseases for clinical diagnosis and search applications.
MGI is transforming the clinical landscape with its expanded range of instruments tailored to the clinical market. Through strategic collaborations with third-party companies on clinical NGS solutions, we are committed to providing precise and cost-effective answers to the various challenges of clinical microbiology, said LudwigOrtner Eurlings, Head of Business Development of MGI Europe and Africa. The launch of the DNBSEQ-E25 marks a significant milestone, allowing laboratories that handle fewer samples to have unprecedented access to next-generation sequencing technology. This advancement allows these laboratories to provide more accurate reports to patients faster, improving diagnostic outcomes and revolutionizing patient care.
Introducing MGI’s Advanced Life Sciences Product Portfolio at ESCMID Global2024
In addition to the DNBSEQ-E25, several products from MGI’s portfolio of advanced laboratory automation, sequencing platforms and metagnomic microbiome sequencing platform will be on display for customers and partners to discover, including the flagship product DNBSEQ-E25. -T7, an ultra-high bitrate sequencer capable of reaching more than 20,000WGS 30 times per year, and the DNBSEQ-G99 which boasts one of the fastest speeds in the world among those with the same bitrate. Additionally, the company introduced two automated sample preparation systems, MGISP-960 and MGISP-Smart8, the automated high-throughput sample transfer processing system, MGISTP-7000, as well as the MGI platform for Rapid microbial identification (PFI) with an integrated species database for simplified analysis of high-throughput genetic sequencing of over 27,600 microorganisms.
In line with our global brand campaign What If We Had A Choice! Launched last year, MGI has enabled scientists and healthcare professionals around the world to benefit from its cutting-edge technology and innovative products. We are excited to have the opportunity to meet them at ESCMID Global2024, while unveiling MGI’s latest DNBSEQ-E25, a portable sequencer designed to perform sequencing and reporting on the go, said Dr. Nicole Neubauer, Director of marketing of MGI Europe and Africa. Additionally, we will present our groundbreaking contribution to MMHP through DNBSEQtm technology, demonstrate the rapid pathogen detection workflow on the DNBSEQ-G99, and share our collaboration with ABL Diagnostics.
MGI welcomes all customers, distributors and partners to stand D23, located in hall 7 of Fira Barcelona Gran Viato discover first-hand its high-quality sequencers and automation platforms and learn more ABOUT them.
About MGI
MGI Tech Co. Ltd. (or its subsidiaries, collectively referred to as MGI), whose head office is located Shenzhen, is committed to creating essential tools and technologies to advance life sciences through intelligent innovation. Based on its proprietary technology, MGI focuses on the research and development, production and sales of sequencing instruments, reagents and related products to support life science research, agriculture, precision medicine and healthcare. MGI is a leading producer of high-throughput clinical gene sequencers, and its multiomics platforms include gene sequencing, medical imaging and laboratory automation. MGI’s mission is to develop and promote advanced life sciences tools for tomorrow’s healthcare. For more information, please see the MGI websiteor contact us on Twitter,LinkedInOrYoutube.
ABOUT ABL DIAGNOSTICS
ABLDiagnosticsS.A. (ABLD) is a world-leading international company providing innovative and proprietary molecular biology assays and end-to-end solutions for use in polymerase chain reaction (PCR) molecular detection. UltraGene and for gnotyping by DNA sequencing? DeepChek.
ABL Diagnostics, based in Woippy, is a public company listed in compartment B of the Euronext regulated market. Paris (Euronext: ABLD ? ISIN: FR001400AHX6). These molecular biology products generate recurring revenue and cover one of the largest portfolios of applications in microbiology.
ABLDiagnostics markets its entire range of products worldwide through its own sales team and a network of exclusive distributors active on all continents. ABLDiagnostics’ clients are university clinical pathology laboratories, private reference laboratories and researchers wishing to implement innovative and robust microbiological content that is constantly expanding.
For more information, please seewww.abldiagnostics.com.
Photo – https://a-a-4-en.e24n.com/en/wp-content/uploads/2024/05/MGI-Showcases-Excellence-in-Life-Sciences-at-ESCMID-Global-2024.jpg
Logo –https://a-a-4-en.e24n.com/en/wp-content/uploads/2024/05/1714631238_989_MGI-Showcases-Excellence-in-Life-Sciences-at-ESCMID-Global-2024.jpg
These press releases may also interest you
|
Communiqué sent on May 1, 2024 10:32 p.m. and distributed by:
